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AbstrAct
The full British Thoracic Society (BTS) guideline for the 
use of long- term macrolides in adults with respiratory 
disease is published in Thorax. The following is a 
summary of the recommendations and good practice 
points. The sections referred to in the summary refer to 
the full guideline. The appendices are available in the full 
guideline and online appendices are available on the BTS 
website. This is the first BTS guideline to use the Grading 
of Recommendations, Assessment, Development and 
Evaluations (GRADE) approach as part of the process of 
guideline development and the guideline was used to pilot 
the new methodology.
IntroductIon
The full guideline for the use of long- term 
macrolides in adults with respiratory disease is 
published in Thorax.1 The key features of the 
methodology and guideline are highlighted 
in a short article published to accompany the 
full guideline.2 The following is a summary 
of the recommendations and good practice 
points (GPPs). The sections referred to in the 
summary refer to the full guideline.
bAckground
The aim of this guideline was to examine the 
evidence for the use of long- term, low- dose 
macrolide agents used in the therapy of adult 
respiratory diseases, to develop guidance for 
clinicians in the use of these agents.
The guideline covers the use of macrolide 
in adults (>16 years) where the duration of 
treatment exceeds that usually employed to 
treat an acute infection and the dosage is 
less than that usually employed to treat an 
acute infection. Such usage is considered 
to be exerting an effect through mecha-
nisms other than a direct antibacterial one, 
commonly described as immunomodulatory 
mechanisms. We have characterised this as 
long- term, low- dose usage.
In addition, the Guideline Development 
Group (GDG) has looked at safety issues 
surrounding the long- term use of macro-
lides at both patient and population levels 
to help to formulate pragmatic guidance in 
this area based on the best available evidence 
combined with clinical experience.
tArget AudIence for the guIdelIne
The guidelines will be of interest to the 
UK- based clinicians caring for adults with 
respiratory disease, including respiratory 
physicians, acute/general medicine physi-
cians and respiratory specialist nurses. The 
guidelines may also be of interest to general 
practitioners, community matrons and prac-
tice nurses, hospice staff and community 
respiratory teams, physiotherapists, micro-
biologists, pathologists, pharmacists, haema-
tologists and lung transplant teams.
AreAs covered by the guIdelIne
This guideline covers the following respira-
tory conditions: asthma, bronchiectasis, 
chronic obstructive pulmonary disease 
(COPD), bronchiolitis obliterans, chronic 
cough, organising pneumonia and diffuse 
panbronchiolitis.
The guideline excludes paediatric prac-
tice. The use of macrolides in cystic fibrosis 
has not been included recognising the 
parallel work of the National Institute for 
Health and Care Excellence 3 in this area. 
Long- term macrolides for chronic rhinosi-
nusitis have not been included. The use of 
macrolides as antibacterial agents to treat 
respiratory infection is excluded.
Methodology
This is the first British Thoracic Society (BTS) 
guideline to use the GRADE approach as 
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Table 1 Summary of outcome measures
Population Intervention Control Outcomes
Adults with asthma Long- term, 
low- dose 
macrolides
Placebo  ► Quality of life measures
 ► Symptom improvement/symptom score
 ► Exacerbation rates
 ► Hospital admission rate
 ► Disease progression and changes in lung function 
tests
 ► Mortality
 ► Exercise capacity/tolerance
 ► Sputum volume/colour/character and 
microbiological resistance/dysbiosis
 ► Drug monitoring/side effects/toxicity
Adults with bronchiectasis
Adults with COPD
Adults with bronchiolitis obliterans
Adults with chronic cough
Adults with organising pneumonia
Adults with diffuse panbronchiolitis
COPD, chronic obstructive pulmonary disease.
Table 2 Categories of evidence
Characteristics Confidence
High Based on consistent results from well- performed 
randomised controlled trials
Further research is very unlikely to change the estimate of the effect
Moderate Based on randomised controlled trials where there is 
evidence of bias, or from other well- conducted study 
types (eg, well- executed observational studies)
Further research is likely to have an impact on the estimate of the 
effect
Low Based on observational evidence, or from controlled 
trials with several serious limitations
Further research is likely to have an important impact
Very low Based on case studies or expert opinion Estimates of effect are far from certain and more research is needed
part of the process of guideline development. Previous 
guidelines have used the SIGN methodology. BTS has 
made this change to reflect common practice in guide-
line development internationally across all medical 
specialities. The advantages of the GRADE approach are 
described in detail in the GRADE handbook and the BTS 
GRADE guideline production manual (https://www. brit- 
thoracic. org. uk/ quality- improvement/ guidelines/).
An accompanying article has been published in Thorax 
which provides additional background.2
clInIcAl questIons, pAtIent centred outcoMes And 
lIterAture seArch
Clinical questions were formulated in the PICO (patient, 
intervention, comparison and outcome) format. The 
PICO framework was used to define the scope of the 
guideline and formed the basis of the literature search. 
The initial search was completed in February 2017, with 
a subsequent search perfumed later in 2017 by York 
University. Systematic electronic database searches were 
conducted to identify all papers which might poten-
tially be included in the guideline. For each question, 
the following databases were searched: Cochrane Data-
base of Systematic Reviews, Database of Abstracts of 
Reviews of Effects, Health Technology Assessment Data-
base, Cochrane Central Register of Controlled Trials, 
MEDLINE and MEDLINE In- Process, Embase and 
PubMed. The search strategy is available for review in 
online appendix 1.
In line with GRADE, a series of patient- centred 
outcomes were identified by the group when the scope 
was agreed (see table 1).
ApprAIsAl And grAdIng of evIdence
Each relevant paper was appraised by outcome(s), to 
generate the best estimate of the effect on each outcome 
and an index of the uncertainty associated with that 
estimate where possible. An evidence profile entry was 
completed for each outcome which included grading of 
the quality of the evidence. The type of evidence available 
for each outcome varied from systematic reviews to case 
series; for each outcome, the highest- quality evidence avail-
able was included. GRADEpro was used to generate the 
evidence profiles, published online on the BTS website 
where they are available for review (see online appendix 
2). The GRADE approach to rating the quality of evidence 
begins with the study design (table 2) and then, through 
a process of considered judgement, applies five reasons 
to possibly rate down the quality of evidence and three 
reasons to possibly rate up the quality (table 3).
In assessing the evidence, the GDG combined low 
and very low evidence into one category (low) as the 
body of evidence was limited.
drAftIng the guIdelIne And MAkIng recoMMendAtIons
The GDG reviewed each clinical question during the 
regular meetings and consensus was reached. Having 
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Table 3 Decreasing and increasing the grade of evidence
Decrease grade if*  ► Serious or very serious limitation to study quality
 ► Important inconsistencies in results
 ► Some or major uncertainty about directness of the evidence
 ► Imprecise or sparse data (relatively few participants and/or events)
 ► High probability of reporting bias
Increase grade if  ► Magnitude of the treatment effect is very large and consistent
 ► Evidence of a large dose- response relation
 ► All plausible confounders/biases would have decreased the magnitude of an apparent treatment effect
*Each quality criterion can reduce the quality by one or, if very serious, two levels. See BTS GRADE guideline production manual for 
further details (https://www.brit-thoracic.org.uk/quality-improvement/guidelines/).
BTS, British Thoracic Society.
Table 4 Explanation of the terminology used in BTS recommendations
Strength Benefits and risks Implications
Strong. It is recommended and so 
‘offer’
Benefits appear to outweigh the risks (or 
vice versa) for the majority of the target 
group
Most service users would want to or 
should receive this intervention
Conditional. It is suggested and so 
‘consider’
Risks and benefits are more closely 
balanced, or there is more uncertainty in 
likely service users values and preferences
The service users should be supported 
to arrive at a decision based on their 
values and preferences
BTS, British Thoracic Society.
generated evidence profiles for each of the clinical ques-
tions, the GDG as a whole then considered the impor-
tance of each of the outcomes for each clinical question 
and proceeded to grade the overall body of evidence for 
critical and important outcomes.
The GDG went on to decide on the direction and 
strength of recommendations considering the quality of 
the evidence, the balance of desirable and undesirable 
outcomes, and the values and preferences of patients and 
others. GRADE specifies two categories of strength of a 
recommendation as presented in table 4.
From the outset, it was acknowledged that there would 
be little high- quality evidence for some of the clinical 
questions identified. GPPs were developed by consensus 
in areas where there was no quality evidence but the GDG 
felt that some guidance based on the clinical experience 
of the GDG might be helpful to the reader. These are 
indicated as shown below.
 ► Recommended best practice based on the clinical experience of the 
guideline development group
declArAtIons of Interest
All members of the GDG made declarations of interest in 
line with BTS policy and further details can be obtained 
on request from BTS. Guideline Group members are 
listed in appendix 1 to the full guideline.
stAkeholder orgAnIsAtIons
Stakeholders were identified at the outset and were noti-
fied when the guideline was available for public consul-
tation.
suMMAry of recoMMendAtIons And gpps
Asthma
Recommendations
 ► Oral macrolide therapy could be considered to reduce 
exacerbation frequency in adults (50–70 years) with 
ongoing symptoms despite >80% adherence to high- 
dose inhaled steroids (>800 µg/day) and at least one 
exacerbation requiring oral steroids in the past year. 
This recommendation reflects the population within 
the AMAZES randomised controlled trial (RCT) 
which represents the highest- quality evidence of 
macrolide therapy leading to a significant reduction 
in exacerbations. (Conditional)
 ► Treatment with azithromycin should be considered 
for a minimum of 6–12 months to assess evidence of 
efficacy in reducing exacerbations. (Conditional)
 ► Oral macrolide therapy should not be offered as a 
way to reduce oral steroid dose; in some individuals, 
this may result as a consequence of a reduction in 
exacerbations or symptoms. (Strong)
GPPs (also see quick reference guide in online supplementary file 
1)
 ► Optimisation of other asthma therapies, including 
establishing good adherence to inhaled therapies, 
should be performed before considering a trial of 
oral macrolide therapy.
 ► Referral to a respiratory specialist or specialist asthma 
service should be considered prior to initiation of 
macrolide therapy aimed at reducing exacerbation 
frequency.
 ► For safety purposes, an ECG should be performed 
prior to initiation of macrolide therapy to assess QTc 
interval. If QTc is >450 ms for men and >470 ms for 
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women then this is considered a contraindication to 
initiating macrolide therapy. Baseline liver function 
tests (LFTs) should also be measured.
 ► Patients should be counselled about potential adverse 
effects before starting therapy, including gastrointes-
tinal upset, hearing and balance disturbance, cardiac 
effects and microbiological resistance.
 ► Microbiological screening of sputum before and 
during macrolide therapy may be clinically helpful 
in patients who are able to expectorate sputum. This 
would allow monitoring for the development of resist-
ance and detect changes in microbial growth to direct 
appropriate antibiotic therapy if required. However, 
the resource implications of this approach have not 
been assessed.
 ► If oral macrolide therapy is considered, justification 
for ongoing treatment should be guided by clin-
ical response based on specific outcome measures, 
including exacerbation frequency, symptoms and 
quality of life assessed at baseline.
 ► A risk:benefit profile should be considered in 
each individual if significant side effects from oral 
macrolide therapy develop. If gastrointestinal side 
effects occur at the higher dose of azithromycin 
(500 mg three times a week), a dose reduction to 
azithromycin 250 mg three times a week could be 
considered if macrolide therapy has been of clinical 
benefit.
 ► Liver function tests should be checked one month 
after starting treatment and then every 6 months. An 
ECG should be performed one month after starting 
treatment to check for new QTc prolongation. If 
present, treatment should be stopped.
 ► Symptom improvement with macrolide treatment 
may be minimal and not consistent across all people 
with asthma. If macrolide therapy is considered for 
symptom reduction, this should be for a defined 
period (6–12 months) and stopped if no symptomatic 
improvement is seen. Use of a validated symptom 
score, such as the ACQ, may be useful to help to make 
this assessment less subjective.
 ► If the desired clinical outcome is achieved, the 
possibility of breaks in therapy may be considered 
to reduce the treatment burden for patients. It is 
unclear whether this may also reduce antimicrobial 
resistance rates.
bronchiectasis
Recommendations
 ► Long- term macrolide treatment could be offered to 
reduce exacerbations in those with high exacerbation 
rates (ie, three or more per year). (Strong)
 ► The dosing regimens with the greatest supportive 
evidence, when using macrolides to reduce exacer-
bation rates, are azithromycin 500mg three times 
a week, azithromycin 250mg daily, and erythro-
mycin ethylsuccinate 400mg twice a day. Astarting 
dose of azithromycin 250mg three times a week 
could be used to minimise side effect risk with 
subsequent titration according to clinical response 
(Conditional)
 ► When using macrolides to reduce exacerbation 
rates, therapy should be offered for a minimum of 6 
months. (Strong)
 ► Macrolides can be considered with the aim of 
improving quality of life but may require a long 
period of therapy (eg, 1 year) for significant effects. 
(Conditional)
GPPs (also see quick reference guide in online supplementary file 
1
 ► Therapies should be optimised in accordance with 
BTS Bronchiectasis Guidelines before considering 
long- term macrolide therapy (eg, airway clearance 
techniques and attendance at pulmonary rehabilita-
tion courses).
 ► Macrolides should only be started following discus-
sion and shared decision- making between the patient 
and a respiratory specialist.
 ► For safety purposes, an ECG should be performed 
prior to initiation of macrolide therapy to assess QTc 
interval. If QTc is >450 ms for men and >470 ms for 
women then this is considered a contraindication to 
initiating macrolide therapy. Baseline LFTs should 
also be measured.
 ► Patients should be counselled about potential adverse 
effects before starting therapy, including gastrointes-
tinal upset, hearing and balance disturbance, cardiac 
effects and microbiological resistance. Microbio-
logical assessment of sputum should be performed 
before therapy, including investigation for NTM. 
Macrolide monotherapy should be avoided if an NTM 
is identified. When evaluating for NTM infection, 
macrolides should not be used for 2 weeks before 
microbiological testing.
 ► Accurate assessment of baseline exacerbation rate 
should be determined before starting long- term 
macrolides for bronchiectasis.
 ► Liver function tests should be checked one month 
after starting treatment and then every 6 months. 
An ECG should be performed 1 month after starting 
treatment to check for new QTc prolongation. If 
present, treatment should be stopped.
 ► Subsequent follow- up at 6 and 12 months should 
determine whether benefit is being derived from 
therapy. If there is no benefit, treatment should be 
stopped.
 ► Even if benefit is seen, consideration should be given 
to stopping treatment for a period each year, for 
example over the summer. Such a drug holiday may 
help with reducing the development of resistance 
whilst maintaining efficacy because the vicious cycle 
has been broken.
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chronic obstructive pulmonary disease
Recommendations
 ► Long- term macrolide therapy could be considered 
for patients with COPD with more than three acute 
exacerbations requiring steroid therapy and at least 
one exacerbation requiring hospital admission per 
year to reduce exacerbation rate. (Conditional)
 ► Long- term macrolide therapy could be considered 
for a minimum of 6 months and up to 12 months to 
assess the impact on exacerbation rate. (Conditional)
GPPs (also see quick reference guide in online supplementary file 
1
 ► Non- pharmacological and pharmacological therapies 
should be optimised prior to considering long- term 
macrolide therapy. This includes smoking cessa-
tion, optimised inhaler technique, optimised self- 
management care plan, airway clearance techniques 
and attendance at pulmonary rehabilitation courses.
 ► Macrolides should only be started following discus-
sion and shared decision- making between the patient 
and a respiratory specialist.
 ► For safety purposes, an ECG should be performed 
prior to initiation of macrolide therapy to assess QTc 
interval. If QTc is >450 ms for men and >470 ms for 
women then this is considered a contraindication to 
initiating macrolide therapy. Baseline LFTs should 
also be measured.
 ► Patients should be counselled about potential adverse 
effects before starting therapy, including gastrointes-
tinal upset, hearing and balance disturbance, cardiac 
effects and microbiological resistance.
 ► Microbiological assessment of sputum should be 
performed before therapy, including investigation for 
NTM. Macrolide monotherapy should be avoided if 
an NTM is identified. Repeat assessments are recom-
mended with clinical decline or during exacerbations 
to monitor resistance patterns.
 ► Accurate assessment of baseline exacerbation rate 
should be determined before starting long- term 
macrolides for patients with COPD and a CT scan 
should be considered to exclude a possible diagnosis 
of bronchiectasis.
 ► A risk:benefit profile should be considered in 
each individual if significant side effects from oral 
macrolide therapy develop. If gastrointestinal side 
effects occur at the higher dose of azithromycin 
(500 mg three times a week), a dose reduction to 
azithromycin 250 mg three times a week could be 
considered if macrolide therapy has been of clinical 
benefit.
 ► Liver function tests should be checked one month 
after starting treatment and then every 6 months. An 
ECG should be performed one month after starting 
treatment to check for new QTc prolongation. If 
present, treatment should be stopped.
 ► Subsequent follow- up at 6 and 12 months should 
determine whether benefit is being derived from 
therapy using objective measures, such as the exacer-
bation rate, CAT score or quality of life as measured 
by a validated assessment tool, such as SGRQ. If there 
is no benefit, treatment should be stopped.
 ► It is not necessary to stop prophylactic azithromycin 
during an acute exacerbation of COPD unless another 
antibiotic with potential to affect the QT interval has 
also been prescribed.
bronchiolitis obliterans (including post-transplantation)
Recommendations
 ► Low- dose, long- term azithromycin (250 mg three 
times a week) could be considered to prevent the 
occurrence of BOS post- lung transplantation. 
(Conditional)
 ► Low- dose azithromycin (250 mg alternate days for 
a trial period of 3 months) could be considered to 
treat BOS occurring in lung transplant recipients. 
(Conditional)
the use of MAcrolIdes In other respIrAtory 
condItIons
cough
Recommendations
 ► Long- term macrolide antibiotics should not be used 
to manage patients with unexplained chronic cough. 
(Conditional)
organising pneumonia
There is insufficient evidence to make a recommenda-
tion.
sAfety Issues
gastro-intestinal effects
Good practice points
 ► Prior to initiating low- dose macrolide therapy, 
patients should be warned of the possibility of gastro-
intestinal side effects.
 ► Gastrointestinal side effects may be ameliorated by 
dose reduction, although this may also reduce clin-
ical efficacy.
 ► Clinicians should carefully consider the risk- to- benefit 
balance when considering therapy for those with pre- 
existing gastrointestinal symptomatology.
cardiac effects
Good practice points
 ► Prior to initiating low- dose macrolide therapy, patients 
should be asked if they have a history of heart disease, 
previous low serum potassium measurements, a slow 
pulse rate, a family history of sudden death or known 
prolonged QT interval. Patients with such a history 
should not receive low- dose macrolide therapy 
without careful consideration and counselling of the 
increased risk of adverse cardiac effects.
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 ► Prior to initiating low- dose macrolide therapy, a drug 
history looking for agents that might prolong the QTc 
interval should be sought (see appendices 3 and 4). 
Patients taking such agents should not receive low- 
dose macrolide therapy.
 ► Prior to initiating low- dose macrolide therapy, an 
ECG should be performed to exclude a prolonged 
QTc interval defined as >450 ms for men and >470 ms 
for women (see section √Methodology in appen-
dices). Patients with a prolonged QTc interval should 
not receive low- dose macrolides.
 ► One month after initiating low- dose macrolide 
therapy, a second ECG should be performed to 
exclude the development of a prolonged QTc interval. 
Patients who develop a prolonged QTc interval on 
low- dose macrolides should stop the macrolide.
 ► If any new drug that could potentially prolong QTc 
time is started or if dose increases are made, repeat 
ECG assessment.
ototoxicity
Good practice point
 ► Prior to initiating low- dose macrolide therapy, 
patients should be asked if they have a history of 
hearing or balance difficulties. Such patients should 
be made aware of the potential for a further, almost 
always reversible, deterioration in hearing or balance 
with macrolide therapy. Patients with pre- existing 
hearing or balance difficulties who wish to proceed 
with treatment should be asked to report any change 
in hearing or balance promptly.
other side effects
Good practice points
 ► Prior to initiating low- dose macrolide therapy, base-
line LFTs should be checked.
 ► LFTs should be checked after one month of treat-
ment and then every six months thereafter for the 
duration of therapy.
AntIMIcrobIAl resIstAnce
good practice points
 ► The risks associated with increasing antimicrobial 
resistance should be discussed with patients prior to 
starting low- dose macrolide therapy. Patients should 
understand the risk that there may not be an effective 
antibiotic for them, or someone else, when needed in 
the future.
 ► Prior to initiating low- dose macrolide monotherapy, 
patients should be asked if they have a history of 
previous or current NTM infection or disease. 
Current NTM infection should be managed with 
reference to BTS guidance and precludes low- dose 
macrolide monotherapy. Successfully treated NTM 
disease should not preclude low- dose macrolide 
monotherapy.
 ► If there is any clinical suspicion of possible NTM 
disease, patients should be screened via examination 
of sputum samples prior to starting therapy. If posi-
tive for recognised potential pathogenic species, low- 
dose macrolide prophylaxis is contraindicated.
dIsclAIMer
Healthcare providers need to use clinical judgement, 
knowledge and expertise when deciding whether it is 
appropriate to apply recommendations for the manage-
ment of patients. The recommendations presented here 
are a guide and may not be appropriate for use in all 
situations. The guidance provided does not override the 
responsibility of healthcare professionals to make deci-
sions appropriate to the circumstances of each patient, 
in consultation with the patient and/or their guardian 
or carer.
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